Finance Foggle

XRP Whale Activity Spikes: CryptoQuant Flags Potential Price Correction Risk Key Takeaways XRP whale exchange inflows jumped to 260 million tokens (30-day moving average) from 141 million in early July 2024 CryptoQuant data shows whale selling patterns that historically preceded price corrections The Enigma Trader first identified this concerning trend in whale behavior Previous similar whale flow patterns led to 12-20% price corrections in XRP Current whale activity mirrors patterns from April and November 2022 correction events Historical data suggests whale outflows typically precede major price rallies of 400%+ Exchange inflows from whales indicate large holders are positioning to sell Binance saw XRP inflows surge to 6-month highs during recent whale activity spikes Whale Money Talks , And It's Speaking Loudly The numbers don't lie. XRP whale inflows to exchanges hit 260 million tokens on the 30-day moving average, up from 141 million at the beginning of July. Someone...

  SEC vs Ripple: Appeals Dropped in Landmark Crypto Case (2025) Key Takeaways SEC and Ripple formally ended their four-year legal battle on August 7, 2025, with both parties dropping appeals Ripple will pay a $125 million civil penalty, now held in escrow for transfer to the U.S. Treasury XRP price jumped over 10% to $3.31 following the announcement The 2023 court ruling remains intact , institutional XRP sales were securities violations, but programmatic sales were not XRP has rallied nearly 99% from April 2025 lows of $1.79 to recent highs of $3.56 Case sets precedent for how crypto tokens are regulated based on sale method rather than token itself The Last Cigarette Burns Out The lawyers packed their briefcases. Four years of depositions, motions, and legal posturing , done. The SEC and Ripple signed off on their mutual destruction pact on August 7, 2025. No more appeals. No more courtroom theatrics. The settlement was as clean as a bar closing at 2 AM. Ripple pays its $...

  Lionsgate Posts Quarterly Loss After 'Ballerina' Disappoints Key Takeaways Lionsgate posted a $94 million net loss in its most recent quarter after spinning off Starz The "John Wick" spinoff "Ballerina" disappointed at the box office Company revenues reached $555.9 million, beating analyst expectations Loss per share hit 35 cents, worse than the projected 25 cents CEO promises return to growth by fiscal 2027 through cost cuts and AI integration Film division dragged down earnings despite TV unit profits doubling Stock rose over 2% in after-hours trading despite the losses The Numbers Don't Lie , But They Tell Strange Stories Lionsgate just dropped a $94 million loss on shareholders. The studio that gave us "John Wick" and "The Hunger Games" now sits naked without its Starz streaming arm, counting quarters like a broke gambler after a bad night. The company pushed out three films this quarter. "The Studio" landed on ...

  Trump Nominates Stephen Miran as New Fed Governor, Replacing Kugler Until Jan 2026 Key Takeaways Trump nominated Stephen Miran, current Council of Economic Advisers Chairman, to fill Adriana Kugler's vacant Fed governor seat This is a temporary appointment lasting until January 31, 2026 Miran co-authored the controversial "Mar-A-Lago Accord" proposing dollar devaluation He previously criticized Fed's aggressive COVID stimulus measures The nomination comes as Trump pressures the Fed for lower interest rates Miran holds a Ph.D. in economics from Harvard Adriana Kugler resigned without stating reasons, though her term was set to expire in January Trump Makes His Fed Play Trump announced Thursday he selected Stephen Miran, chair of the Council of Economic Advisors, to serve on the central bank. The guy doesn't waste time. Trump said Miran "has been with me from the beginning of my Second Term, and his expertise in the World of Economics is unparalleled....

  Want to Beat the Nasdaq? Try Dividends Key Takeaways Strategy 2025 Performance Key Benefit Risk Level Dividend Leaders Index Outperformed broader market Consistent income + growth Medium High-Yield Utilities Leading returns in 2025 Stability during volatility Low-Medium Dividend Growth Stocks Sustained long-term gains Compound growth potential Medium Financial Services Dividends Strong 2025 performance Higher yields than tech Medium-High Quick Answer : Yes, dividend strategies are beating the Nasdaq in 2025. Dividend strategies have outperformed the broader stock market in 2025, with utilities and financial services leading the charge while tech stumbles. Why Dividend Stocks Are Crushing the Nasdaq in 2025 Something weird happened in 2025 - dividend stocks started winning again. Tech companies burned billions while promising "future growth," but dividend payers just kept sending quarterly checks to shareholders. Utilities jumped 18%, financials climbed 15%, while ...

  S&P 500 Flattens on Report of Waller as Trump's Preferred Fed Chair Pick Key Takeaways Key Point Details Market Impact S&P 500 trimmed early gains Thursday amid Fed independence concerns Leading Candidate Christopher Waller's odds surged to 51% on prediction markets Policy Stance Waller recently dissented, voting for 25bp rate cut Timeline Fed chair selection expected before Powell's term ends in May 2026 Eliminated Candidates Treasury Secretary Scott Bessent no longer under consideration Market Reaction: S&P 500 Loses Steam on Fed Chair Speculation The S&P 500 gave up its morning gains Thursday after reports surfaced that Christopher Waller emerged as Trump's top pick for Federal Reserve chair. Markets don't like uncertainty, and this news created exactly that kind of worry among investors. I've seen this pattern before during my years watching Fed transitions. The market initially celebrates any clarity on leadership picks, then qui...

FDA Approves Breakthrough Eye Drops That Fix Near Vision Without Glasses Key Takeaways Aspect Details Latest FDA Approval VIZZ eye drops approved July 2025, works up to 10 hours Active Ingredient Aceclidine 1.44% - first of its kind in the US How Long It Works Up to 10 hours per dose with once-daily application Effectiveness 71% of users gained 3+ lines of near vision improvement Availability Expected launch between October-December 2025 Other Options Vuity (pilocarpine) and QLOSI also FDA-approved Who Can Use It Adults with presbyopia (age-related near vision loss) Cost Coverage Insurance coverage varies, prescription required What Are These Revolutionary Eye Drops? The FDA just approved VIZZ, the first and only aceclidine-based eye drop for treating presbyopia, marking a global first in this treatment category. This isn't your grandfather's reading glasses solution - we're talking about drops that can give you clear near vision for up to 10 hours with just one d...